Ocugen Q4 2025 net loss $0.06/share; OCU400 Phase 3 enrollment complete; cash $18.9M

Ocugen, Inc.

Fourth quarter 2025 net loss $0.06 per share (vs $0.05 Q4 2024); full year net loss $0.23 per share (vs $0.20).
Cash and restricted cash $18.9M at Dec 31, 2025 ($58.8M year-end 2024); January 2026 raised $22.5M via stock offering led by RTW Investments.
OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa completed enrollment (140 patients); topline data expected Q1 2027.
OCU410ST Phase 2/3 GARDian trial nearing enrollment completion; interim data Q3 2026; OCU410 Phase 2 showed 46% lesion growth reduction.
Exclusive Korean rights to OCU400 licensed to Kwangdong Pharmaceutical with upfront fees and milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ocugen, Inc. reported financial results for the fourth quarter and the fiscal year ended December 31, 2025.

Period: the fourth quarter and the fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 4, 2026, Ocugen, Inc. (the “Company”) issued a press release announcing certain financial results for the fourth quarter and the fiscal year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-023288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.